{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:47:38Z","timestamp":1770709658177,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:00:00Z","timestamp":1536364800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11096-018-0703-z","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T03:38:54Z","timestamp":1536377934000},"page":"1528-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price"],"prefix":"10.1007","volume":"40","author":[{"given":"Mari\u00e1ngeles","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Villama\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Jim\u00e9nez-N\u00e1cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamaida","family":"Plasencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,8]]},"reference":[{"key":"703_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.berh.2011.02.002","volume":"24","author":"J Zochling","year":"2010","unstructured":"Zochling J, Smith EUR. Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol. 2010;24:747\u201356.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"703_CR2","first-page":"554","volume":"28","author":"S Hukuda","year":"2001","unstructured":"Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554\u20139.","journal-title":"J Rheumatol"},{"key":"703_CR3","first-page":"498","volume":"28","author":"S Mu\u00f1oz-Fern\u00e1ndez","year":"2010","unstructured":"Mu\u00f1oz-Fern\u00e1ndez S, de Miguel E, Cobo-Ib\u00e1\u00f1ez T, Carmona L, Steiner M, Descalzo MA, et al. Early spondyloarthritis: results from the pilot registry ESPIDEP. Clin Exp Rheumatol. 2010;28:498\u2013503.","journal-title":"Clin Exp Rheumatol"},{"key":"703_CR4","doi-asserted-by":"crossref","unstructured":"Quintana G, Coral-Alvarado P. Economic impact of rheumatic diseases. Chall Rheumatol [Internet]. 2011. \n                    http:\/\/www.intechopen.com\/books\/challenges-in-rheumatology\/economic-impact-of-rheumatic-diseases\n                    \n                  . Citado 5 marzo 2018.","DOI":"10.5772\/26724"},{"key":"703_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol Hoboken NJ. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"703_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"703_CR7","doi-asserted-by":"publisher","first-page":"ii124","DOI":"10.1136\/annrheumdis-2012-202350","volume":"72","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(suppl 2):ii124\u20137.","journal-title":"Ann Rheum Dis"},{"key":"703_CR8","unstructured":"Informe t\u00e9cnico ANTI-TNF-reumatolog\u00eda. infliximab_y_adalimumab.pdf [Internet]. \n                    http:\/\/sescam.castillalamancha.es\/sites\/sescam.castillalamancha.es\/files\/documentos\/farmacia\/infliximab_y_adalimumab.pdf\n                    \n                  . Cited 8 March 2018."},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4258","volume":"15","author":"C Plasencia","year":"2013","unstructured":"Plasencia C, Pascual-Salcedo D, Garc\u00eda-Carazo S, Lojo L, Nu\u00f1o L, Villalba A, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther. 2013;15:R79.","journal-title":"Arthritis Res Ther"},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"703_CR11","first-page":"372","volume":"31","author":"R Ariza-Ariza","year":"2004","unstructured":"Ariza-Ariza R, Hern\u00e1ndez-Cruz B, Navarro-Sarabia F. La versi\u00f3n espa\u00f1ola del BASDAI es fiable y se correlaciona con la actividad de la enfermedad. Rev Esp Reumatol. 2004;31:372\u20138.","journal-title":"Rev Esp Reumatol"},{"key":"703_CR12","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"703_CR13","unstructured":"Real Decreto Legislativo 3\/2011, de 14 de noviembre, por el que se aprueba el texto refundido de la Ley de Contratos del Sector P\u00fablico [Internet]. Noticias Jur\u00eddicas. \n                    http:\/\/noticias.juridicas.com\/base_datos\/Admin\/rdleg3-2011.html\n                    \n                  . Cited 11 March 2018."},{"key":"703_CR14","first-page":"4","volume":"17","author":"MAG Gonz\u00e1lez Fern\u00e1ndez","year":"2015","unstructured":"Gonz\u00e1lez Fern\u00e1ndez MAG, Ramos FM, Hugo AV, Plasencia C, Salcedo DP, Pinto PH, et al. Anti-TNF dose and anti-drug antibody levels in rheumatic and psoriasis patients: economic repercussion. Eur J Clin Pharm. 2015;17:4.","journal-title":"Eur J Clin Pharm"},{"key":"703_CR15","unstructured":"Real Decreto-ley 4\/2010, de 26 de marzo, de racionalizaci\u00f3n del gasto farmac\u00e9utico con cargo al Sistema Nacional de Salud. BOE.es\u2014Documento BOE-A-2010-5030 [Internet]. \n                    https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2010-5030\n                    \n                  . Cited 11 March 2018."},{"key":"703_CR16","unstructured":"Anuncio de formalizaci\u00f3n de contratos de: Direcci\u00f3n del Instituto Nacional de Gesti\u00f3n Sanitaria (INGESA). Objeto: Acuerdo Marco para la selecci\u00f3n de suministradores de medicamentos inmunosupresores para varias Comunidades Aut\u00f3nomas y Organismos de la Administraci\u00f3n del Estado. Expediente: AM 13\/160.BOE-B-2014-9305.pdf [Internet]. \n                    https:\/\/www.boe.es\/boe\/dias\/2014\/03\/15\/pdfs\/BOE-B-2014-9305.pdf\n                    \n                  . Cited 17 Oct 2017."},{"issue":"5","key":"703_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","volume":"16","author":"Louis P. Garrison","year":"2013","unstructured":"Garrison Jr. LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, et al. Performance-based risk-sharing arrangements\u2014good practice for design, implementation and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Show Value Health. 2013;16:703\u2013719. \n                    https:\/\/www.ispor.org\/ValueInHealth\/ShowValueInHealth.aspx?issue=5E4EB78D-D58F-48A3-9FD7-E96C7B626C11\n                    \n                  . Cited 17 Oct 2017.","journal-title":"Value in Health"},{"key":"703_CR18","first-page":"233","volume":"2","author":"FG-D Rueda","year":"2017","unstructured":"Rueda FG-D, Robles-Rodr\u00edguez L, Tena-Sempere ME, L\u00f3pez AML, Zafra-L\u00f3pez F, Horno IE, et al. An\u00e1lisis y evaluaci\u00f3n del coste del tratamiento anti-TNFalfa en artritis reumatoide y espondilitis anquilosante. Dosis individualizadas frente a comercializadas. J Negat No Posit Results. 2017;2:233\u20139.","journal-title":"J Negat No Posit Results"},{"key":"703_CR19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s11096-015-0124-1","volume":"37","author":"V Escudero-Vilaplana","year":"2015","unstructured":"Escudero-Vilaplana V, Ram\u00edrez-Herr\u00e1iz E, Ala\u00f1\u00f3n-Plaza E, Trovato-L\u00f3pez N, Garc\u00eda-Vicu\u00f1a R, Carre\u00f1o-P\u00e9rez L, et al. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Int J Clin Pharm. 2015;37:808\u201314.","journal-title":"Int J Clin Pharm"},{"key":"703_CR20","first-page":"181","volume":"27","author":"A Martiarena Ayestar\u00e1n","year":"2017","unstructured":"Martiarena Ayestar\u00e1n A, Mart\u00ednez Mart\u00ednez C, M\u00ednguez Cabeza AC. Estudio del coste de las terapias biol\u00f3gicas en patolog\u00edas reum\u00e1ticas seg\u00fan pr\u00e1ctica cl\u00ednica de un hospital. Rev OFIL. 2017;27:181\u20136.","journal-title":"Rev OFIL"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nu\u00f1o L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatol Oxf Engl. 2011;50:1445\u201352.","journal-title":"Rheumatol Oxf Engl"},{"key":"703_CR22","unstructured":"Pascual-Salcedo D, Plasencia C, Jurado T, Valle LG del, Sabina P, Diego C, et al. Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness. J Pharmacovigil. 2015;3. \n                    https:\/\/www.omicsonline.org\/open-access\/dosetapering-of-tnf-inhibitors-in-daily-rheumatology-practice-enables-the-maintenance-of-clinical-efficacy-while-improving-costeffectiveness-2329-6887-1000172.php?aid=58635\n                    \n                  . Cited 21 Oct 2017."},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"e000259","DOI":"10.1136\/rmdopen-2016-000259","volume":"2","author":"R Westhovens","year":"2016","unstructured":"Westhovens R, Annemans L. Costs of drugs for treatment of rheumatic diseases. RMD Open. 2016;2:e000259.","journal-title":"RMD Open"},{"key":"703_CR24","unstructured":"Guidelines on evaluation of similar biotherapeutic products (SBPs). \n                    http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/biological_therapeutics\/Guidelines_Biotherapeutic_products_FINAL_HK_IK_12_June.pdf\n                    \n                  . Cited 8 July 2017."},{"key":"703_CR25","unstructured":"Inflectra. Product information; Inflectra; INN: infliximab-WC500151490.pdf [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002778\/WC500151490.pdf\n                    \n                  . Cited 8 July 2017."},{"key":"703_CR26","unstructured":"Remsima. Product information, INN: infliximab-WC500151486.pdf [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002576\/WC500151486.pdf\n                    \n                  . Cited 8 July 2017."},{"key":"703_CR27","unstructured":"Benepali. Product information, INN-etanercept-WC500200380.pdf [Internet]. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\n                    \n                  . Cited 8 July 2017."},{"key":"703_CR28","unstructured":"Real Decreto 177\/2014, de 21 de marzo, por el que se regula el Sistema de precios de referencia y de agrupaciones homog\u00e9neas de medicamentos en el Sistema Nacional de Salud, y determinados sistemas de informaci\u00f3n en materia de financiaci\u00f3n y precios de los medicamentos y productos sanitarios BOE-A-2014-3189.pdf [Internet]. \n                    https:\/\/www.boe.es\/boe\/dias\/2014\/03\/25\/pdfs\/BOE-A-2014-3189.pdf\n                    \n                  . Cited Oct 2017."},{"key":"703_CR29","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3748\/wjg.v21.i6.1728","volume":"21","author":"F Rencz","year":"2015","unstructured":"Rencz F, P\u00e9ntek M, Bortlik M, Zagorowicz E, Hlavaty T, \u015aliwczy\u0144ski A, et al. Biological therapy in inflammatory bowel diseases: access in central and eastern Europe. World J Gastroenterol WJG. 2015;21:1728\u201337.","journal-title":"World J Gastroenterol WJG"},{"key":"703_CR30","doi-asserted-by":"publisher","first-page":"A558","DOI":"10.1016\/j.jval.2013.08.1465","volume":"16","author":"G McCarthy","year":"2013","unstructured":"McCarthy G, Bitoun CE, Guy H. introduction of an infliximab biosimilar (ct-p13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health. 2013;16:A558.","journal-title":"Value Health"},{"key":"703_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10198-013-0538-4","volume":"15","author":"M-I Farfan-Portet","year":"2014","unstructured":"Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ HEPAC Health Econ Prev Care. 2014;15:223\u20138.","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"key":"703_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/FTD.0000000000000410","volume":"39","author":"G Paintaud","year":"2017","unstructured":"Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, et al. Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Ther Drug Monit. 2017;39:339\u201343.","journal-title":"Ther Drug Monit"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0703-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T09:05:12Z","timestamp":1568192712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0703-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0703-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,8]]},"assertion":[{"value":"26 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest have been declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}